USD
Reduce targetBefore 20.09%Target 20%
Cash allocation. No separate rationale was supplied.
Strategy decision
Loading the recorded decision…
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Targets, reasoning, and execution evidence will appear here.
Strategy decision
Sep 18, 2026, 8:19 AM EDT
Using this strategy in your portfolio? Open the Builder to review its source targets. Review your saved portfolio →
The decision
This 80% invested, 20% cash portfolio favors disclosed earnings and more disciplined valuations across managed care, providers, pharmaceuticals, diagnostics, and devices. CI, BMY, ELV, HCA, and DVA anchor the valuation case; MDT adds reported growth and dividend support. Cash preserves flexibility while avoiding concentration and retaining eight diversified healthcare holdings.
Targets & reasoning
Before is the portfolio weight captured at decision time. Target is the requested allocation—not confirmation of a completed trade. These are simulated strategy weights, not personalized allocations.
Cash allocation. No separate rationale was supplied.
I expect CI to contribute durable returns because its 10.94 P/E and $25.24 TTM diluted EPS provide a measured valuation starting point, while its 2.24% trailing dividend yield supports total return. I'm wrong if earnings durability weakens or valuation discipline no longer holds.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect BMY to enhance portfolio income and value because its $4.65 TTM diluted EPS is valued at a 13.51 P/E and its trailing dividend yield is 3.99%. I'm wrong if earnings durability or dividend support weakens, particularly after the 7.06% 20-session decline.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect ELV to compound steadily because TTM diluted EPS is $27.75 at a 14.93 P/E, and shares returned 3.97% over 20 sessions. This pairs valuation discipline with improving near-term confirmation. I'm wrong if earnings durability erodes or the positive trend reverses materially.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect HCA to add resilient provider exposure because its TTM diluted EPS of $27.39 is valued at a 15.66 P/E, while its 20-session return was 5.40%. I'm wrong if earnings durability deteriorates or the recent strength fails to persist.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: months
I expect MDT to recover constructively because disclosed commentary cites 13.7% revenue growth, 40.7% EPS growth, raised guidance, and a 3.07% trailing dividend yield. I'm wrong if the reported growth and guidance momentum fail to translate into durable earnings.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: quarters
I expect GILD to contribute measured total return because its 2.15% trailing dividend yield supplies income and the shares gained 2.23% over 20 sessions, offering current confirmation without a concentrated allocation. I'm wrong if the dividend support weakens or the positive trend reverses.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: months
I expect DVA to add disciplined services exposure because its $11.51 TTM diluted EPS is valued at a 15.91 P/E and shares returned 3.28% over 20 sessions. I'm wrong if earnings durability deteriorates or recent operating-market confirmation reverses.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: months
I expect DGX to provide a modest diagnostics allocation because shares gained 2.35% over 20 sessions and its $9.71 TTM diluted EPS supports a clearly disclosed, though higher, 25.48 P/E valuation. I'm wrong if earnings durability weakens or valuation becomes less supportable.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: medium · Horizon: months
Exit JNJ because its 30.64 P/E is less disciplined than the cheaper earnings-backed alternatives retained, while its 20-session return was -1.17%; capital is better assigned to more measured valuation exposure.
Recorded Sep 18, 2026, 8:19 AM EDT · Conviction: high · Horizon: weeks
Portfolio checks
The complete proposal passed the versioned universe, cash, concentration, and posture constraints without platform modification.
These checks cover portfolio constraints. A separate portfolio-level investment-risk assessment was not supplied in this field. Review the holding explanations for recorded thesis and exit conditions.
Ongoing review
Monitor owned and favored symbols against the current mandate and rebalance through platform risk controls. Monitor for mandate drift. Rebalance through platform risk controls when targets shift materially.
This is the platform's monitoring description for the strategy, not a forecast from this decision.
Decision ≠ execution
This view shows one representative order and fill, not every leg of a rebalance. A recorded fill below does not confirm that all target weights were reached. Open the strategy portfolio to inspect current holdings.
Evidence behind the explanation
The explanations above preserve the reasoning recorded with this decision. The record details below show processing and execution history. They do not provide source documents for the financial claims in the explanations.
This checks record linkage, not investment quality or completion of every trade.
These identify processing inputs and validation steps. They are not linked research sources.
Healthcare Quality cycle started by scheduled.
Healthcare Quality produced a canonical target-weight decision.
Created sell proposal for DGX-USD.
Risk engine approved proposal 01M2T7DQSCF9876P7GNP1ZCNEK.
Queued sell order for DGX-USD for MOO execution.
Healthcare Quality cycle completed with status pending_fill.
Healthcare Quality valuation snapshot recorded for agent_cycle_run 01M2T7C6MT6Y38K6B45AMBQXY0.
Assumed MOO sell fill for DGX-USD at the verified session open.
Simulated sell fill for DGX-USD at the verified MOO session open.
Recorded balanced ledger entries for assumed MOO fill.